title: Chimeric CD4 monoclonal antibody cM-T412 as a therapeutic approach to rheumatoid arthritis.
abstract: OBJECTIVE
  To investigate the effects of chimeric CD4 monoclonal antibody cM-T412 treatment in patients with rheumatoid arthritis (RA).
  
  
  METHODS
  Thirty-two RA patients received daily doses of 10, 50, or 100 mg of cM-T412 intravenously for 7 days.
  
  
  RESULTS
  There was a sustained decrease in the number of CD4+ T lymphocytes in all patients. Those who received 50 mg and 100 mg of the antibody experienced significant reductions in disease activity.
  
  
  CONCLUSIONS
  Treatment with cM-T412 appears to have a dose-dependent beneficial effect in RA patients. The clinical effects of cM-T412 are independent of the depressed numbers of circulating CD4+ T cells.
authors.affiliation: Department of Rheumatology, University Hospital Leiden, The Netherlands.
authors.forename: P A
authors.initials: PA
authors.lastname: van der Lubbe
authors.forename: C
authors.initials: C
authors.lastname: Reiter
authors.forename: F C
authors.initials: FC
authors.lastname: Breedveld
authors.forename: K
authors.initials: K
authors.lastname: Krüger
authors.forename: M
authors.initials: M
authors.lastname: Schattenkirchner
authors.forename: M E
authors.initials: ME
authors.lastname: Sanders
authors.forename: G
authors.initials: G
authors.lastname: Riethmüller
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000276:immunology* / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000503:physiopathology / Q000628:therapy*; D015704:CD4 Antigens / Q000276:immunology*; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008297:Male; D008875:Middle Aged; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D012720:Severity of Illness Index
chemical_list: D000911:Antibodies, Monoclonal; D015704:CD4 Antigens; D011993:Recombinant Fusion Proteins